This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.
The assay under development at the University of Pennsylvania is based on a microarray platform of 8 arrays by 60,000 probes and detects all known viruses and other pathogenic bacteria, fungi, and parasites, covering more than 6,000 accessions of microorganisms associated with diseases.
The array-based technology can accurately detect an agent of interest, including SARS-CoV-2, in less than 24 hours. The assay includes probes covering all known pathogenic respiratory pathogens, including other coronaviruses from bats and other mammals, providing accurate and efficient detection of SARS-CoV-2 as well as the potential for detection of other respiratory pathogens as co-infecting agents that may contribute to severity of disease.
Dr. Erle Robertson of the University of Pennsylvania will describe the benefits of the test, which include high accuracy due to the use of multiple probes across the genome, which minimizes negative results from probe failure due to the compensatory signals from other probes in the assay screen.
Dr. Robertson will discuss his team’s plans to develop the assay to require only a few drops of blood or plasma for detection of the virus.
Disclaimer: Agilent products are NOT approved for COVID-19 testing, diagnosis, treatment, or mitigation. Agilent has not validated a product to detect the novel coronavirus.
For Research Use Only. Not for use in diagnostic procedures.